Table 3.

Summary of treatment-emergent adverse events (safety population)

Patients, n (%)	GP MDI 7.2 μg, n=62	GP MDI 14.4 μg, n=63	GP MDI 28.8 μg, n=61	Placebo MDI, n=65
Patients with ≥1 TEAE	7 (11.3)	6 (9.5)	5 (8.2)	6 (9.2)
Patients with TEAEs related to study treatmenta	1 (1.6)	1 (1.6)	0	1 (1.5)
Patients with serious TEAEs	0	0	0	1 (1.5)
Patients with serious TEAEs related to study treatmenta	0	0	0	1 (1.5)
Patients with TEAEs leading to early discontinuation	0	0	0	1 (1.5)
Deaths	0	0	0	0
TEAEs reported in ≥2 patients in any treatment group
Nasopharyngitis	1 (1.6)	2 (3.2)	0	1 (1.5)
Rash	0	0	2 (3.3)	0

Note:

^aRelated = possible, probably, or definitely related to study drug in the opinion of the investigator.

Abbreviations: GP, glycopyrronium; MDI, metered dose inhaler; TEAE, treatment-emergent adverse event.